CN116426021A - 一种靶向性含镓蛋白修饰sebs膜的制备方法及其应用 - Google Patents
一种靶向性含镓蛋白修饰sebs膜的制备方法及其应用 Download PDFInfo
- Publication number
- CN116426021A CN116426021A CN202310329791.1A CN202310329791A CN116426021A CN 116426021 A CN116426021 A CN 116426021A CN 202310329791 A CN202310329791 A CN 202310329791A CN 116426021 A CN116426021 A CN 116426021A
- Authority
- CN
- China
- Prior art keywords
- gallium
- sebs film
- solution
- sebs
- film
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052733 gallium Inorganic materials 0.000 title claims abstract description 57
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 42
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- -1 styrene-ethylene-butylene-styrene Chemical class 0.000 title abstract description 12
- 230000008685 targeting Effects 0.000 title abstract description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 46
- 239000011521 glass Substances 0.000 claims abstract description 36
- 238000002791 soaking Methods 0.000 claims abstract description 35
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims abstract description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000011780 sodium chloride Substances 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 19
- 230000001954 sterilising effect Effects 0.000 claims abstract description 15
- 239000011248 coating agent Substances 0.000 claims abstract description 6
- 238000000576 coating method Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 230000003213 activating effect Effects 0.000 claims abstract description 3
- 229920001935 styrene-ethylene-butadiene-styrene Polymers 0.000 claims abstract 33
- 239000000243 solution Substances 0.000 claims description 80
- 238000001035 drying Methods 0.000 claims description 44
- 239000011259 mixed solution Substances 0.000 claims description 42
- 235000018102 proteins Nutrition 0.000 claims description 38
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 claims description 34
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical group C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 claims description 23
- 239000012965 benzophenone Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 239000008096 xylene Substances 0.000 claims description 20
- 229940044658 gallium nitrate Drugs 0.000 claims description 17
- 238000008416 Ferritin Methods 0.000 claims description 15
- 238000004140 cleaning Methods 0.000 claims description 14
- 229940078795 lactoferrin Drugs 0.000 claims description 14
- 239000012581 transferrin Substances 0.000 claims description 13
- 102000008857 Ferritin Human genes 0.000 claims description 11
- 108050000784 Ferritin Proteins 0.000 claims description 11
- 102000010445 Lactoferrin Human genes 0.000 claims description 11
- 108010063045 Lactoferrin Proteins 0.000 claims description 11
- 102000004338 Transferrin Human genes 0.000 claims description 11
- 108090000901 Transferrin Proteins 0.000 claims description 11
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 11
- 235000021242 lactoferrin Nutrition 0.000 claims description 11
- 239000010453 quartz Substances 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- 238000011010 flushing procedure Methods 0.000 claims description 8
- 239000000178 monomer Substances 0.000 claims description 8
- 230000010355 oscillation Effects 0.000 claims description 8
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 7
- UPWPDUACHOATKO-UHFFFAOYSA-K gallium trichloride Chemical compound Cl[Ga](Cl)Cl UPWPDUACHOATKO-UHFFFAOYSA-K 0.000 claims description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical group Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 4
- AJNVQOSZGJRYEI-UHFFFAOYSA-N digallium;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Ga+3].[Ga+3] AJNVQOSZGJRYEI-UHFFFAOYSA-N 0.000 claims description 4
- 229910001195 gallium oxide Inorganic materials 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 16
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 4
- 238000011068 loading method Methods 0.000 abstract description 4
- 239000012620 biological material Substances 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 230000018883 protein targeting Effects 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 230000000844 anti-bacterial effect Effects 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 14
- 241000191967 Staphylococcus aureus Species 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 10
- 239000008367 deionised water Substances 0.000 description 10
- 229910021641 deionized water Inorganic materials 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000005520 cutting process Methods 0.000 description 9
- 238000009210 therapy by ultrasound Methods 0.000 description 9
- ISAOCJYIOMOJEB-UHFFFAOYSA-N benzoin Chemical compound C=1C=CC=CC=1C(O)C(=O)C1=CC=CC=C1 ISAOCJYIOMOJEB-UHFFFAOYSA-N 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 5
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 244000028419 Styrax benzoin Species 0.000 description 3
- 235000000126 Styrax benzoin Nutrition 0.000 description 3
- 235000008411 Sumatra benzointree Nutrition 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 229960002130 benzoin Drugs 0.000 description 3
- 238000006482 condensation reaction Methods 0.000 description 3
- 235000019382 gum benzoic Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- CKHJYUSOUQDYEN-UHFFFAOYSA-N gallium(3+) Chemical compound [Ga+3] CKHJYUSOUQDYEN-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/12—Chemical modification
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
- A01N25/10—Macromolecular compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
- A01N59/16—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J5/00—Manufacture of articles or shaped materials containing macromolecular substances
- C08J5/18—Manufacture of films or sheets
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/12—Chemical modification
- C08J7/14—Chemical modification with acids, their salts or anhydrides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/12—Chemical modification
- C08J7/16—Chemical modification with polymerisable compounds
- C08J7/18—Chemical modification with polymerisable compounds using wave energy or particle radiation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2353/00—Characterised by the use of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives of such polymers
- C08J2353/02—Characterised by the use of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives of such polymers of vinyl aromatic monomers and conjugated dienes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Pest Control & Pesticides (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dentistry (AREA)
- Inorganic Chemistry (AREA)
- Agronomy & Crop Science (AREA)
- Manufacturing & Machinery (AREA)
- Toxicology (AREA)
- Materials Engineering (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及生物材料技术领域,公开了一种靶向性含镓蛋白修饰SEBS膜的制备方法及其应用,制备方法包括以下步骤:步骤一、将SEBS粉末与二甲苯溶液混合后涂覆到玻璃板上,待二甲苯挥发后,将所述玻璃板浸泡在水中,直至将SEBS膜从所述玻璃板上取下;步骤二、将所述SEBS膜置于光引发剂中浸泡后,通过紫外接枝在其表面修饰羧基;步骤三、将蛋白均匀分散在NaCl溶液中后,加入含镓溶液,振荡;步骤四、将接枝后的SEBS膜活化后置于步骤三所得溶液中浸泡,得靶向性含镓蛋白修饰SEBS膜。本发明通过蛋白靶向细菌,将镓离子送入细菌体内,可以减少镓离子的损耗,实现高效杀菌的效果,同时通过反复负载镓离子可以实现多次杀菌。
Description
技术领域
本发明涉及生物材料技术领域,特别涉及一种靶向性含镓蛋白修饰SEBS膜的制备方法及其应用。
背景技术
细菌作为地球上最古老的生物之一,数量丰富,分布广泛,对人类生活造成了巨大影响。它是许多疾病的病原体,可以通过各种方式(如接触、呼吸道和昆虫叮咬)在人体之间传播。细菌感染是由细菌引起的疾病之一,是外科手术中最常见的并发症之一。早期,人类使用抗生素暂时解决细菌感染问题。然而,不久之后,许多细菌种类逐渐对常见抗生素产生了耐药性。到目前为止,全球细菌耐药性情况非常严重,应该说所有细菌都已被发现具有耐药性,对抗菌药物完全敏感的细菌几乎不存在,甚至出现了超级耐药细菌,如耐甲氧西林金黄色葡萄球菌(MRSA)、耐万古霉素金黄色葡萄球菌(VRSA)、耐多药铜绿假单胞菌(MDR-PA)。因此,控制细菌感染必须采取有效的不会诱导多重耐药性的策略。
液态金属镓(Ga)是一种新型抗菌材料。在室温下,镓呈液态,在其表面形成致密的氧化膜,防止进一步氧化。它具有许多其他显著的特点,如良好的生物相容性、低毒性、良好的导电性和导热性以及形状变形性。这一特性正好证实了镓可以应用于人体,同时它具有比其他金属基抗菌材料更有利的抗菌性能。镓(Ⅲ)可以在细菌的代谢循环中取代铁(Ⅲ)(这可以抑制细菌中的含铁酶,并增加氧化剂敏感性。)以抑制细菌的生长。
发明内容
发明目的:针对现有技术中存在的问题,本发明提供一种靶向性含镓蛋白修饰SEBS膜的制备方法及其应用,通过紫外接枝在SEBS表面修饰上羧基,利用缩合反应将含镓蛋白连接到SEBS膜上,实现靶向性含镓蛋白修饰SEBS膜的制备。本发明通过蛋白靶向细菌,将镓离子送入细菌体内,可以减少镓离子的损耗,实现高效杀菌的效果,同时通过反复负载镓离子可以实现多次杀菌效果。
技术方案:本发明提供了一种靶向性含镓蛋白修饰SEBS膜的制备方法,包括以下步骤:
步骤一、将SEBS粉末加至二甲苯溶液中混合均匀,得混合溶液,将所述混合溶液涂覆到玻璃板表面,待所述混合溶液中的二甲苯完全挥发后得到SEBS膜,将具有所述SEBS膜的玻璃板浸泡在水中,直至将SEBS膜从所述玻璃板表面取下;
步骤二、将所述SEBS膜置于光引发剂中浸泡后取出、干燥,将接枝单体溶液滴加到干燥后的SEBS膜上,用石英片盖住,在紫外光下反应,然后清洗、干燥,得接枝后的SEBS膜;
步骤三、将蛋白均匀分散在NaCl溶液中后,加入含镓溶液,振荡;
步骤四、将所述接枝后的SEBS膜浸泡在活化剂中进行活化处理,然后用PBS冲洗,接着将冲洗后的SEBS膜置于步骤三所得溶液中2-8 h后取出,清洗、干燥,得靶向性含镓蛋白修饰SEBS膜。
进一步地,步骤一中,所述SEBS粉末与二甲苯溶液质量体积比为1:6-1:9。
进一步地,步骤二中,所述光引发剂为二苯甲酮。
进一步地,步骤二中,所述接枝单体溶液中的接枝单体为甲基丙烯酸。
和/或,步骤二中,所述接枝单体溶液的浓度为1-2 M,接枝时间为1-10 min。
进一步地,步骤三中,所述含镓溶液为硝酸镓、氧化镓和氯化镓中的任一种。
和/或,步骤三中,所述含镓溶液的浓度为5-10 mM。
进一步地,步骤三中,所述蛋白为转铁蛋白、乳铁蛋白和铁蛋白中的任一种;
和/或,步骤三中,所述NaCl溶液的浓度为0.09%-0.9%。
进一步地,步骤四中,所述活化剂为1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐和N-羟基琥珀酰亚胺。
进一步地,所述1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐和N-羟基琥珀酰亚胺的摩尔比为20-50%。
优选地,步骤三中,所述振荡具体条件如下:
振荡时间为8-12 h,振荡温度为20-40 ℃,振荡转速为70-150 rpm。
优选地,步骤二中,所述浸泡时间为10-30 mins;
和/或,步骤四中,所述浸泡时间为10-15 h。
本发明还提供了一种如上述任一项所述方法制备的靶向性含镓蛋白修饰SEBS膜的应用,所述靶向性含镓蛋白修饰SEBS膜使用后,置于紫外灯下灭菌处理,清洗、烘干,接着用硝酸镓溶液浸泡,振荡10-11 h,清洗、干燥,即可恢复其杀菌效果。
有益效果:与现有技术相比,本发明通过在SEBS基底上接枝羧基基团,使之可以与蛋白连接,随后利用摇床,将蛋白和含镓溶液振荡混合,再利用缩合反应将含镓蛋白连接到SEBS膜上,实现含镓蛋白修饰SEBS膜的制备;本发明利用紫外接枝技术在SEBS表面修饰羧基,利用缩合反应将含镓蛋白连接到SEBS膜上,制备了一种靶向性含镓蛋白修饰SEBS膜,该膜可通过蛋白的靶向细菌作用,将镓离子送入细菌体内,减少镓离子的消耗,利用镓离子的铁代谢阻断机理,破坏细菌的DNA合成,使其无法增殖,并破坏其体内抗氧化系统,诱导ROS的产生,同时通过反复负载镓离子可以实现多次杀菌效果。该方法简单易行,工艺简单,实现了靶向循环抗菌。
附图说明
图1是本发明制备靶向性含镓蛋白修饰SEBS膜对大肠杆菌抗菌效果图;
图2是本发明制备靶向性含镓蛋白修饰SEBS膜对金黄色葡萄球菌抗菌效果图。
具体实施方式
下面结合附图对本发明进行详细的介绍。
实施方式1:
将3g SEBS粉末加入20 ml二甲苯溶液里搅拌,直至完全溶解且没有气泡,将混合溶液均匀涂覆在玻璃板上,待二甲苯完全挥发,将玻璃板浸泡在水中,直至SEBS膜可以从玻璃板上轻轻取下。将制备好的SEBS膜切成1×1 cm2的片状,分别用水和乙醇超声清洗,烘干后备用。
将0.15g 二苯甲酮(BP)加入到10 ml的乙醇中,搅拌混合均匀。将备用的SEBS膜浸泡在BP溶液中30 min,取出后干燥,全程避光处理。待干燥后,将100 μl甲基丙烯酸滴加到SEBS膜上,盖上石英片,在紫外光下照射6 min,去离子水冲掉残余溶液,烘箱干燥。将接枝好的SEBS膜浸泡在EDC/NHS混合溶液中12 h;将5 mg转铁蛋白加入1 ml 0.09% NaCl溶液中,超声,使其均匀分散在NaCl溶液中,向混合溶液中加入1ml硝酸镓溶液,振荡12 h;PBS冲洗浸泡后的SEBS膜,并浸泡在硝酸镓和转铁蛋白的混合溶液中,5 h后取出,冲洗,干燥,实现镓-转铁蛋白修饰SEBS膜的制备。
对样品进行抗菌测试,利用平板计数法,对大肠杆菌和金黄色葡萄球菌杀菌率均达90%以上,得到结果见表1。
实施方式2:
将2g SEBS粉末加入16 ml二甲苯溶液里搅拌,直至完全溶解且没有气泡,将混合溶液均匀涂覆在玻璃板上,待二甲苯完全挥发,将玻璃板浸泡在水中,直至SEBS膜可以从玻璃板上轻轻取下。将制备好的SEBS膜切成1×1 cm2的片状,分别用水和乙醇超声清洗,烘干后备用。
将0.15 g二苯甲酮(BP)加入到10 ml的乙醇中,搅拌混合均匀。将备用的SEBS膜浸泡在BP溶液中30 min,取出后干燥,全程避光处理。待干燥后,将100 μl甲基丙烯酸滴加到SEBS膜上,盖上石英片,在紫外光下照射6 min,去离子水冲掉残余溶液,烘箱干燥。将接枝好的SEBS膜浸泡在EDC/NHS混合溶液中12 h;将3 mg乳铁蛋白加入1 ml 0.09% NaCl溶液中,超声,使其均匀分散在NaCl溶液中,向混合溶液中加入1 ml硝酸镓溶液,振荡10 h;PBS冲洗浸泡后的SEBS膜,并浸泡在硝酸镓和乳铁蛋白的混合溶液中,5 h后取出,冲洗,干燥,实现镓-乳铁蛋白修饰SEBS膜的制备。
对样品进行抗菌测试,利用平板计数法,对大肠杆菌和金黄色葡萄球菌杀菌率均达93%以上,得到结果见表1。
实施方式3:
将3g SEBS粉末加入23 ml二甲苯溶液里搅拌,直至完全溶解且没有气泡,将混合溶液均匀涂覆在玻璃板上,待二甲苯完全挥发,将玻璃板浸泡在水中,直至SEBS膜可以从玻璃板上轻轻取下。将制备好的SEBS膜切成1×1 cm2的片状,分别用水和乙醇超声清洗,烘干后备用。
将0.15g二苯甲酮(BP)加入到10 ml的乙醇中,搅拌混合均匀。将备用的SEBS膜浸泡在BP溶液中30 min,取出后干燥,全程避光处理。待干燥后,将100 μl甲基丙烯酸滴加到SEBS膜上,盖上石英片,在紫外光下照射6 min,去离子水冲掉残余溶液,烘箱干燥。将接枝好的SEBS膜浸泡在EDC/NHS混合溶液中12 h;将4 mg转铁蛋白加入1 ml 0.09% NaCl溶液中,超声,使其均匀分散在NaCl溶液中,向混合溶液中加入2 ml硝酸镓溶液,振荡10 h;PBS冲洗浸泡后的SEBS膜,并浸泡在硝酸镓和转铁蛋白的混合溶液中,5 h后取出,冲洗,干燥,实现镓-铁蛋白修饰SEBS膜的制备。
对样品进行抗菌测试,测试完成后在紫外灯下灭菌处理12 h且用去离子水超声清洗,烘干后,将其浸泡在2 ml硝酸镓溶液中,振荡10 h,冲洗,干燥,对样品再次进行抗菌测试,利用平板计数法,对大肠杆菌和金黄色葡萄球菌杀菌率均达95%以上,得到结果见表1。
对比例1:
将3gSEBS粉末加入20ml二甲苯溶液里搅拌,直至完全溶解且没有气泡,将混合溶液均匀涂覆在玻璃板上,待二甲苯完全挥发,将玻璃板浸泡在水中,直至SEBS膜可以从玻璃板上轻轻取下。将制备好的SEBS膜切成1×1 cm2的片状,分别用水和乙醇超声清洗,烘干后备用。
将0.15g 二苯甲酮(BP)加入到10ml的乙醇中,搅拌混合均匀。将备用的SEBS膜浸泡在BP溶液中30 min,取出后干燥,全程避光处理。待干燥后,将100 μl丙烯酰胺滴加到SEBS膜上,盖上石英片,在紫外光下照射6 min,去离子水冲掉残余溶液,烘箱干燥。将接枝好的SEBS膜浸泡在EDC/NHS混合溶液中12 h;将5 mg转铁蛋白加入1 ml 0.09% NaCl溶液中,超声,使其均匀分散在NaCl溶液中,向混合溶液中加入1 ml硝酸镓溶液,振荡12 h;PBS冲洗浸泡后的SEBS膜,并浸泡在硝酸镓和转铁蛋白的混合溶液中,5 h后取出,冲洗,干燥,实现镓-转铁蛋白修饰SEBS膜的制备。
对样品进行抗菌测试,利用平板计数法,发现对大肠杆菌和金黄色葡萄球菌无明显杀菌效果,得到结果见表1。
对比例2:
将3g SEBS粉末加入20 ml二甲苯溶液里搅拌,直至完全溶解且没有气泡,将混合溶液均匀涂覆在玻璃板上,待二甲苯完全挥发,将玻璃板浸泡在水中,直至SEBS膜可以从玻璃板上轻轻取下。将制备好的SEBS膜切成1×1 cm2的片状,分别用水和乙醇超声清洗,烘干后备用。
将0.15 g二苯甲酮(BP)加入到10 ml的乙醇中,搅拌混合均匀。将备用的SEBS膜浸泡在BP溶液中30min,取出后干燥,全程避光处理。待干燥后,将100 μl丙烯酰胺滴加到SEBS膜上,盖上石英片,在紫外光下照射6 min,去离子水冲掉残余溶液,烘箱干燥。将接枝好的SEBS膜浸泡在EDC/NHS混合溶液中12 h;将3 mg乳铁蛋白加入1ml 0.09% NaCl溶液中,超声,使其均匀分散在NaCl溶液中,向混合溶液中加入2 ml硝酸镓溶液,振荡12 h;PBS冲洗浸泡后的SEBS膜,并浸泡在硝酸镓和乳铁蛋白的混合溶液中,5 h后取出,冲洗,干燥,实现镓-乳铁蛋白修饰SEBS膜的制备。
对样品进行抗菌测试,利用平板计数法,发现对大肠杆菌和金黄色葡萄球菌无明显杀菌效果,得到结果见表1。
对比例3:
将3g SEBS粉末加入23.3 ml二甲苯溶液里搅拌,直至完全溶解且没有气泡,将混合溶液均匀涂覆在玻璃板上,待二甲苯完全挥发,将玻璃板浸泡在水中,直至SEBS膜可以从玻璃板上轻轻取下。将制备好的SEBS膜切成1×1 cm2的片状,分别用水和乙醇超声清洗,烘干后备用。
将0.15 g安息香加入到10 ml的乙醇中,搅拌混合均匀。将备用的SEBS膜浸泡在BP溶液中30 min,取出后干燥,全程避光处理。待干燥后,将100 μl甲基丙烯酸滴加到SEBS膜上,盖上石英片,在紫外光下照射6 min,去离子水冲掉残余溶液,烘箱干燥。将接枝好的SEBS膜浸泡在EDC/NHS混合溶液中12 h;将3 mg乳铁蛋白加入1ml 0.09% NaCl溶液中,超声,使其均匀分散在NaCl溶液中,向混合溶液中加入1 ml氯化镓溶液,振荡12 h;PBS冲洗浸泡后的SEBS膜,并浸泡在氯化镓和乳铁蛋白的混合溶液中,4 h后取出,冲洗,干燥,实现镓-乳铁蛋白修饰SEBS膜的制备。
对样品进行抗菌测试,利用平板计数法,发现对大肠杆菌和金黄色葡萄球菌无明显杀菌效果,得到结果见表1。
对比例4:
将3g SEBS粉末加入23.3 ml二甲苯溶液里搅拌,直至完全溶解且没有气泡,将混合溶液均匀涂覆在玻璃板上,待二甲苯完全挥发,将玻璃板浸泡在水中,直至SEBS膜可以从玻璃板上轻轻取下。将制备好的SEBS膜切成1×1 cm2的片状,分别用水和乙醇超声清洗,烘干后备用。
将0.15g二苯甲酮(BP)加入到10ml的乙醇中,搅拌混合均匀。将备用的SEBS膜浸泡在BP溶液中30 min,取出后干燥,全程避光处理。待干燥后,将100 μl丙烯酰胺滴加到SEBS膜上,盖上石英片,在紫外光下照射6 min,去离子水冲掉残余溶液,烘箱干燥。将接枝好的SEBS膜浸泡在EDC/NHS混合溶液中12 h;将5 mg铁蛋白加入1ml 0.09% NaCl溶液中,超声,使其均匀分散在NaCl溶液中,向混合溶液中加入1 ml氯化镓溶液,振荡12 h;PBS冲洗浸泡后的SEBS膜,并浸泡在氯化镓和铁蛋白的混合溶液中,5 h后取出,冲洗,干燥,实现镓-铁蛋白修饰SEBS膜的制备。
对样品进行抗菌测试,利用平板计数法,对大肠杆菌和金黄色葡萄球菌杀菌率无明显杀菌效果,得到结果见表1。
对比例5:
将3g SEBS粉末加入23.3 ml二甲苯溶液里搅拌,直至完全溶解且没有气泡,将混合溶液均匀涂覆在玻璃板上,待二甲苯完全挥发,将玻璃板浸泡在水中,直至SEBS膜可以从玻璃板上轻轻取下。将制备好的SEBS膜切成1×1 cm2的片状,分别用水和乙醇超声清洗,烘干后备用。
将0.15 g安息香加入到10ml的乙醇中,搅拌混合均匀。将备用的SEBS膜浸泡在BP溶液中30 min,取出后干燥,全程避光处理。待干燥后,将100 μl丙烯酰胺滴加到SEBS膜上,盖上石英片,在紫外光下照射6 min,去离子水冲掉残余溶液,烘箱干燥。将接枝好的SEBS膜浸泡在EDC/NHS混合溶液中12 h;将5 mg铁蛋白加入1 ml 0.09% NaCl溶液中,超声,使其均匀分散在NaCl溶液中,向混合溶液中加入1 ml硝酸镓溶液,振荡10 h;PBS冲洗浸泡后的SEBS膜,并浸泡在硝酸镓和铁蛋白的混合溶液中,5 h后取出,冲洗,干燥,实现镓-铁蛋白修饰SEBS膜的制备。
对样品进行抗菌测试,利用平板计数法,发现对大肠杆菌和金黄色葡萄球菌无明显杀菌效果,得到结果见表1。
对比例6:
将3 g SEBS粉末加入23.3 ml二甲苯溶液里搅拌,直至完全溶解且没有气泡,将混合溶液均匀涂覆在玻璃板上,待二甲苯完全挥发,将玻璃板浸泡在水中,直至SEBS膜可以从玻璃板上轻轻取下。将制备好的SEBS膜切成1×1 cm2的片状,分别用水和乙醇超声清洗,烘干后备用。
将0.15 g安息香加入到10 ml的乙醇中,搅拌混合均匀。将备用的SEBS膜浸泡在BP溶液中30 min,取出后干燥,全程避光处理。待干燥后,将100 μl甲基丙烯酸滴加到SEBS膜上,盖上石英片,在紫外光下照射6 min,去离子水冲掉残余溶液,烘箱干燥。将接枝好的SEBS膜浸泡在EDC/NHS混合溶液中12 h;将3 mg铁蛋白加入1 ml 0.09% NaCl溶液中,超声,使其均匀分散在NaCl溶液中,向混合溶液中加入2 ml氧化镓溶液,振荡10 h;PBS冲洗浸泡后的SEBS膜,并浸泡在氧化镓和铁蛋白的混合溶液中,5 h后取出,冲洗,干燥,实现镓-铁蛋白修饰SEBS膜的制备。
对样品进行抗菌测试,利用平板计数法,对大肠杆菌和金黄色葡萄球菌杀菌率无明显杀菌效果,得到结果见表1。
表1本发明对比例1-6及实施方式1-3得到的功能表面杀菌测试结果
杀菌率 | 实施方式1 | 实施方式2 | 实施方式3 | 对比例1 | 对比例2 | 对比例3 | 对比例4 | 对比例5 | 对比例6 |
大肠杆菌 | 90% | 93% | 96% | 5% | 8% | 3% | 3% | 6% | 0 |
金黄色葡萄球菌 | 91.5% | 94.4% | 95% | 5% | 3% | 2% | 5% | 8% | 0 |
通过对比例1-6与实施方式1-3杀菌测试结果对照可知,本发明制备得到的靶向性含镓蛋白修饰的SEBS膜可以有效的杀死周围细菌并且实现反复负载镓离子多次杀菌效果。
上述实施方式只为说明本发明的技术构思及特点,其目的在于让熟悉此项技术的人能够了解本发明的内容并据以实施,并不能以此限制本发明的保护范围。凡根据本发明精神实质所做的等效变换或修饰,都应涵盖在本发明的保护范围之内。
Claims (10)
1.一种靶向性含镓蛋白修饰SEBS膜的制备方法,其特征在于,包括以下步骤:
步骤一、将SEBS粉末加至二甲苯溶液中混合均匀,得混合溶液,将所述混合溶液涂覆到玻璃板表面,待所述混合溶液中的二甲苯完全挥发后得到SEBS膜,将具有所述SEBS膜的玻璃板浸泡在水中,直至将SEBS膜从所述玻璃板表面取下;
步骤二、将所述SEBS膜置于光引发剂中浸泡后取出、干燥,将接枝单体溶液滴加到干燥后的SEBS膜上,用石英片盖住,在紫外光下反应,然后清洗、干燥,得接枝后的SEBS膜;
步骤三、将蛋白均匀分散在NaCl溶液中后,加入含镓溶液,振荡;
步骤四、将所述接枝后的SEBS膜浸泡在活化剂中进行活化处理,然后用PBS冲洗,接着将冲洗后的SEBS膜置于步骤三所得溶液中2-8h后取出,清洗、干燥,得靶向性含镓蛋白修饰SEBS膜。
2.根据权利要求1所述的靶向性含镓蛋白修饰SEBS膜的制备方法,其特征在于,步骤一中,所述SEBS粉末与二甲苯溶液质量体积比为1:6-1:9。
3.根据权利要求1所述的靶向性含镓蛋白修饰SEBS膜的制备方法,其特征在于,步骤二中,所述光引发剂为二苯甲酮;
和/或,步骤二中,所述接枝单体溶液中的接枝单体为甲基丙烯酸;
和/或,步骤二中,所述接枝单体溶液的浓度为1-2 M,接枝时间为1-10 min。
4.根据权利要求1所述的靶向性含镓蛋白修饰SEBS膜的制备方法,其特征在于,步骤三中,所述含镓溶液为硝酸镓、氧化镓和氯化镓中的任一种;
和/或,步骤三中,所述含镓溶液的浓度为5-10 mM。
5.根据权利要求1所述的靶向性含镓蛋白修饰SEBS膜的制备方法,其特征在于,步骤三中,所述蛋白为转铁蛋白、乳铁蛋白和铁蛋白中的任一种;
和/或,步骤三中,所述NaCl溶液的浓度为0.09%-0.9%。
6.根据权利要求1所述的靶向性含镓蛋白修饰SEBS膜的制备方法,其特征在于,步骤四中,所述活化剂为1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐和N-羟基琥珀酰亚胺。
7.根据权利要求6所述的靶向性含镓蛋白修饰SEBS膜的制备方法,其特征在于,所述1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐和N-羟基琥珀酰亚胺的摩尔比为20-50%。
8.根据权利要求1所述的靶向性含镓蛋白修饰SEBS膜的制备方法,其特征在于,步骤三中,所述振荡具体条件如下:
振荡时间为8-12 h,振荡温度为20-40 ℃,振荡转速为70-150 rpm。
9. 根据权利要求1所述的靶向性含镓蛋白修饰SEBS膜的制备方法,其特征在于,步骤二中,所述浸泡时间为10-30 mins;
和/或,步骤四中,所述浸泡时间为10-15 h。
10. 一种如权利要求1-9中任一项所述方法制备的靶向性含镓蛋白修饰SEBS膜的应用,其特征在于,所述靶向性含镓蛋白修饰SEBS膜使用后,置于紫外灯下灭菌处理,清洗、烘干,接着用硝酸镓溶液浸泡,振荡10-11 h,清洗、干燥,即可恢复其杀菌效果。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310329791.1A CN116426021B (zh) | 2023-03-30 | 一种靶向性含镓蛋白修饰sebs膜的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310329791.1A CN116426021B (zh) | 2023-03-30 | 一种靶向性含镓蛋白修饰sebs膜的制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116426021A true CN116426021A (zh) | 2023-07-14 |
CN116426021B CN116426021B (zh) | 2024-06-21 |
Family
ID=
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101011596A (zh) * | 2007-02-08 | 2007-08-08 | 浙江理工大学 | 一种抗菌肽改性丝蛋白膜材料的制备方法 |
CN101781645A (zh) * | 2010-01-25 | 2010-07-21 | 哈尔滨商业大学 | 固定化酶膜的制备方法 |
US20160082151A1 (en) * | 2013-05-16 | 2016-03-24 | South China University Of Technology | Antibacterial cornea repair material and preparation method thereof |
CN110818941A (zh) * | 2019-10-08 | 2020-02-21 | 淮阴工学院 | 一种近红外光响应型杀菌-脱粘附褶皱表面的制备方法 |
US20200390104A1 (en) * | 2018-02-26 | 2020-12-17 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Antimicrobial gallium compounds and methods |
WO2022253107A1 (zh) * | 2021-05-30 | 2022-12-08 | 浙江大学 | 甲基丙烯酰化乳清蛋白水凝胶的制备方法及应用 |
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101011596A (zh) * | 2007-02-08 | 2007-08-08 | 浙江理工大学 | 一种抗菌肽改性丝蛋白膜材料的制备方法 |
CN101781645A (zh) * | 2010-01-25 | 2010-07-21 | 哈尔滨商业大学 | 固定化酶膜的制备方法 |
US20160082151A1 (en) * | 2013-05-16 | 2016-03-24 | South China University Of Technology | Antibacterial cornea repair material and preparation method thereof |
US20200390104A1 (en) * | 2018-02-26 | 2020-12-17 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Antimicrobial gallium compounds and methods |
CN110818941A (zh) * | 2019-10-08 | 2020-02-21 | 淮阴工学院 | 一种近红外光响应型杀菌-脱粘附褶皱表面的制备方法 |
WO2022253107A1 (zh) * | 2021-05-30 | 2022-12-08 | 浙江大学 | 甲基丙烯酰化乳清蛋白水凝胶的制备方法及应用 |
Non-Patent Citations (6)
Title |
---|
PANELFENGJUN SHI等: "A novel antimicrobial strategy for bacterial infections: Gallium-based materials", 《COLLOID AND INTERFACE SCIENCE COMMUNICATIONS》, vol. 56, 30 September 2023 (2023-09-30), pages 100735 * |
YOSHITAKA MORIWAKI†等: "Molecular Basis of Recognition of Antibacterial Porphyrins by Heme-Transporter IsdH-NEAT3 of Staphylococcus aureus", 《BIOCHEMISTRY》, vol. 50, no. 34, 31 December 2011 (2011-12-31), pages 7311 * |
吕毅华;李昕;刘周;李家斌;王岱;薛云新;赵西林;: "镓在抗菌方面的研究进展", 中国抗生素杂志, no. 04, 27 April 2018 (2018-04-27), pages 35 - 41 * |
施杰源: "蛋白质功能化及基于蛋白交联构建抗凝抗菌表面的研究", 《中国优秀硕士学位论文全文数据库 (工程科技Ⅰ辑)》, no. 2, 15 February 2024 (2024-02-15), pages 020 - 32 * |
王梦露;潘文文;: "抗菌PLGA薄膜的初步研究", 郑州轻工业学院学报(自然科学版), no. 2, pages 44 - 48 * |
甘胜华;邓建元;杨万泰;: "光接枝表面改性聚丙烯膜固定蛋白质的研究", 北京化工大学学报(自然科学版), no. 04, 20 July 2008 (2008-07-20), pages 63 - 66 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108816689B (zh) | 一种具有长效抗菌性能的超亲水涂层及其制备方法 | |
Kim et al. | Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm | |
CN101010003B (zh) | 抗微生物的银组合物 | |
JP5735990B2 (ja) | 発芽誘導物質と抗菌剤とを含む組成物 | |
Shineh et al. | Biofilm formation, and related impacts on healthcare, food processing and packaging, industrial manufacturing, marine industries, and sanitation–a review | |
CN111471202B (zh) | 一种抗菌硅橡胶材料及其制备方法和应用 | |
EP3423099B1 (en) | Use of bile acids and bile salts as anti bacterial agents for inhibition of bacterial conjugation and horizontal gene transfer | |
CN107670506A (zh) | 一种水过滤用抗菌耐污染的pvdf超滤膜的制备方法 | |
CN116426021B (zh) | 一种靶向性含镓蛋白修饰sebs膜的制备方法及其应用 | |
CN108456476A (zh) | 一种光催化空气杀菌净化环保内墙涂料及其制备方法 | |
CN116426021A (zh) | 一种靶向性含镓蛋白修饰sebs膜的制备方法及其应用 | |
Khan et al. | Recent Strategies and Future Recommendations for the Fabrication of Antimicrobial, Antibiofilm, and Antibiofouling Biomaterials | |
Gagon et al. | Antimicrobial light-activated polypropylene modified with chitosan: Characterization and reusability | |
JP2018149536A (ja) | 抗菌剤を表面及びポリマーにクロスリンクするための処方及びプロセス | |
US20230212427A1 (en) | Method for treating a surface and use of collagen hydrolysate for treating a surface | |
CN105543820B (zh) | 一种不锈钢医疗器械表面抗细菌粘附涂层的制备方法 | |
KR20120123321A (ko) | 실리콘 고무 재질로 된 제품의 표면에 대한 살균처리 방법 | |
CN107602901B (zh) | 高密度接枝酸基催化细菌裂解的抗生物被膜材料及其制备方法和应用 | |
CN112043863B (zh) | 能够响应温度变化选择性表达“抗污-促细胞粘附-杀菌”多功能的钛基植入体及制备方法 | |
CN109221102A (zh) | 一种抑菌新材料 | |
JP2003146820A (ja) | 微生物によるカビ付着防止、並び脱臭剤及びそれを用いたカビ付着防止方法、並び脱臭方法。 | |
CN108721248A (zh) | 一种pH响应型纳米银组装体的制备方法、产物及应用 | |
CN112876670B (zh) | 一种抗菌防污的聚合物刷及其制备方法和应用 | |
RU2815980C1 (ru) | Способ повышения эффективности дезинфектантов и состав комбинированных дезинфектантов против биоплёнок бактерий | |
TW201215717A (en) | Method for preparing superabsorbent antibacterial fiber |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |